Ke Geng


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

A member of the firm’s Policy Committee and managing partner of the Beijing office, Ke advises clients across numerous industries in connection with financings for Chinese companies, mergers and acquisitions, and other corporate matters.

Ke has been named one of China’s 100 Elite Lawyers by China Business Law Journal for the past three years.  Prior to entering the legal profession, he earned a B.S. degree in Biology from Peking University and a Ph.D. in Biochemistry from New York University.  Ke led the O’Melveny team for RemeGen’s Hong Kong IPO, which was recognized as Deal of the Year by China Business Law Journal and Megatrend Deal of the Year – Healthcare by FinanceAsia.  Ke is highly rated for China capital markets by Chambers Asia Pacific, Chambers Greater China Region and Chambers Global.


  • Mandarin Chinese

Honors & Awards

  • Named to the “A-List” of China’s 100 Elite Foreign Lawyers by China Business Law Journal, 2020, 2021 and 2022
  • Recognized by Chambers Asia-Pacific and Chambers Greater China Region in the practice area of Capital Markets: Equity (International Firms) - China (2022 and 2023)
  • Recognized by Chambers Global in the practice area of Capital Markets: Equity (China) (2022) and Capital Markets: Equity (International Firms) - China (2023)
  • Recognized by IFLR1000 as a “Notable Practitioner” in the practice area of Mergers & Acquisitions (China) (2019 - 2021)


Bar Admissions

  • New York


  • Northwestern University School of Law, J.D., 2003 
  • New York University, Ph.D., Biochemistry, 2001
  • Peking University, B.S. (Biology), 1994

Professional Activities


  • “Should China Provide Intellectual Property Protection for Genetically Modified Animals?” Northwestern Journal of International Law and Business (Winter 2003) 

Speaking Engagements

  • Practising Law Institute's "Doing Business in and With China 2021" (December, 2021)

Offshore Public Offerings and Capital Markets

Ke regularly advises companies on offshore listings and other capital market financings; his representations amount to an aggregate financing size of over US$20 billion, including:

Life Sciences, Medical and Healthcare:
  • Companies: RemeGen; Akeso Biopharma; Yonghe Medical; Beauty Farm; Shanghai Bio-heart; Luzhu Biotech; Cryofocus Medtech; Sipai Health; 3D Medicines; Gaush Meditech; Jenscare Scientific; Rainmed; Gushengtang; Acotec Scientific; Brii Biosciences; Keymed Biosciences; Jacobio Pharmaceuticals; Simcere Pharmaceutical; Honliv Healthcare; Hygeia Healthcare; Peijia Medical; Shanghai Kindly Medical Instruments; Pharmaron; Aesthetic Medical International (Nasdaq); Hua Medicine; ShangPharma (NYSE); Viva Biotech; Shanghai Haohai Biological; 3S Bio (Nasdaq), and Phoenix Healthcare
  • Underwriters and Sponsors: Shanghai HeartCare Medical (Goldman Sachs and CICC); Hanyu Medical (on-going), and Wuxi AppTech (NYSE, J.P. Morgan and Credit Suisse)
  • Companies: UP Fintech (Nasdaq); Inc. (NYSE); Inc. (NYSE); Yeahka; eHi Car Services (NYSE), and Montage (Nasdaq)
  • Underwriters and Sponsors: 4Paradigm (on-going, Goldman Sachs and CICC); Huafang Group (Haitong International and CCB International); GDS (J.P. Morgan, BofA Securities, CICC and Haitong International); (NYSE, Morgan Stanley, Credit Suisse and Citigroup); Zhongguancun Science-Tech Leasing (Guotai Junan); FingerTango (China Securities (International) Corporate Finance Company Limited); Digital Hollywood (China Securities (International) Corporate Finance Company Limited); Leju Holdings (NYSE, Credit Suisse and J.P. Morgan, China Renaissance, Macquarie Group and China Merchants Securities); Jupai Holdings (NYSE, Cred3it Suisse and China Renaissance); Tarena Technologies (Nasdaq, Credit Suisse and Goldman Sachs); Zero2IPO (Fortune Financial Capital, Fortune Securities, and CICC), and Chen Lin Education Group (First Shanghai Capital)
    China CITIC Bank; China Construction Bank Corporation; Dexin China; Bank of Qingdao; Hengxing Gold; China Polymetallic Mining; China Real Estate Information Corporation (Nasdaq); Yuzhou Group; Crystal River Capital (NYSE, underwriters), and NorthStar Realty Finance Corp. (NYSE)


In the News

China Business Law Journal: Luzhu Biotechnology Launches HKD341m IPO via Chapter 18A

May 10, 2023

China Business Law Journal: O’Melveny Acts on Acotec Scientific’s Partial Offering

February 15, 2023

Global Legal Chronicle: Beauty Farm’s Hong Kong IPO and Listing

January 20, 2023 International: Deal Digest: Hong Kong and Japan See Year-End Growth Momentum, With PRC Firms Tapping US and European Capital Markets For Growth

January 12, 2023

China Business Law Journal: The A-List 2022

January 5, 2023

China Business Law Journal: China’s second largest streaming platform Huafang lists in Hong Kong

December 23, 2022

China Business Law Journal: 3D Medicines Taps Han Kun for IP Advice in Hong Kong IPO

December 22, 2022

China Business Law Journal: Law Firm Quartet Advises Gaush Meditech’s Hong Kong Listing

December 21, 2022

Global Legal Chronicle: Jenscare Scientific’s Hong Kong IPO

October 19, 2022

Global Legal Chronicle: Rainmed Medical’s HK$146 Million IPO and Listing on the Hong Kong Stock Exchange

July 13, 2022

China Business Law Journal: The A-List 2021

January 24, 2022

ICLG: China Hair Company Concludes HKD 1.49 Billion Listing

December 17, 2021 International: Pharma and Tech Listings Run the Gamut on Hong Kong Stock Exchange

December 15, 2021

Press Releases

O’Melveny Represents Luzhu Biotech in its US$43 Million Hong Kong IPO, First for an 18A Biotech Company in 2023

May 8, 2023

Chambers Global Recognizes 29 O'Melveny Lawyers and 13 Practice Groups

March 2, 2023

O’Melveny Advises Acotec Scientific on the First Takeover Offer to a Chapter 18A Biotech Company

February 13, 2023

O’Melveny Represents Beauty Farm in US$100 Million Hong Kong IPO

January 16, 2023

O’Melveny Recommended in China, Korea and Japan by Chambers 2023 Asia-Pacific and Greater China Region Guides

January 13, 2023

O’Melveny Partners Geng Ke and Edwin Kwok Named to China’s “A-List” of Elite 100 Lawyers

January 6, 2023

O’Melveny Represents Cryofocus in its Hong Kong IPO

December 30, 2022

O’Melveny Represents Sipai Health in its Hong Kong IPO

December 23, 2022

O’Melveny Represents 3D Medicines Inc. in US$52 Million Hong Kong IPO

December 15, 2022

O’Melveny Advises Gaush in US$86 Million Hong Kong IPO

December 12, 2022

O’Melveny Represents Sponsors and Underwriters in Hong Kong IPO of Huafang Group Inc.

December 12, 2022

O’Melveny Represents Jenscare Scientific in Its Hong Kong IPO

October 10, 2022

O’Melveny Lawyers and Practice Groups Recommended by IFLR1000 2022-2023 Guide

September 7, 2022

O’Melveny Represents Rainmed Medical in its Hong Kong IPO

July 8, 2022

O’Melveny Receives Top Recognitions from China Business Law Awards 2022

June 16, 2022

Chambers Global Recognizes 29 O’Melveny Lawyers and 11 Practice Groups

February 25, 2022

Geng Ke Named to China’s “A-List” of Elite 100 Lawyers

January 24, 2022

O’Melveny Recommended in China, Korea and Japan by Chambers 2022 Asia-Pacific and Greater China Region Guides

January 13, 2022

O’Melveny Represents Bio-heart in Its Hong Kong IPO

December 23, 2021

O’Melveny Represents Yonghe Medical in US$192 Million Hong Kong IPO

December 13, 2021

O’Melveny Advises Gushengtang in US$104 Million Hong Kong IPO

December 10, 2021

Alerts and Publications